SecBot SecBot
PRESS-RELEASE ·Filed Apr 27, 2026

EVAX

Evaxion
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight • Neutral

Monitor upcoming 10-Q or 20-F filings for any changes in R&D or G&A spending that may reflect the expanded management role. No immediate trading catalyst present.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.18
T+0 close · Apr 27, 2026 · via day close
Latest settled
−27.27%
T+60 · $3.04
Vs SPY
−32.05%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 27 $4.18entry
  2. T+1 · 7mo ago +3.35%α +3.83% · $4.32
  3. T+5 · 7mo ago +9.33%α +8.93% · $4.57
  4. T+20 · 6mo ago −1.67%α −6.63% · $4.11
  5. T+60 · 4mo ago −27.27%α −32.05% · $3.04
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Evaxion promoted its Chief Scientific Officer, Birgitte Rønø, to also serve as Chief Operating Officer to enhance external engagement and strategic execution. The move reflects internal management restructuring but does not involve new financial or operational data.

Key Facts

  • Birgitte Rønø, CSO, promoted to dual role of CSO and COO at Evaxion
  • Promotion aims to strengthen external visibility and strategic execution of the AI-Immunology™ platform
  • No changes to other executive roles; management team remains intact
  • No financial metrics, guidance updates, or material operational changes disclosed

Financial Impact

No immediate financial impact, organizational change without cost or revenue implications disclosed

operating_efficiencymanagement_structure

Risk Factors

  • Potential operational disruption during leadership transition, though risk appears low given internal promotion
  • Forward-looking statements carry uncertainty regarding future partnerships and platform visibility

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3281538

Track record

50 reports on EVAX

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  2. Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  3. Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
  4. Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  5. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  6. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  7. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  8. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
  9. Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
  10. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
Showing 10 of 50

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 27, 2026